---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-109580"
form_type: "8-K"
ticker: "TTRX"
cik: "0002023016"
company_name: "Turn Therapeutics Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:39:25.762619+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Turn Therapeutics Q3 net loss $1.9M; enters global Medline PermaFusion deal

## Summary
- Net loss of $1.9M ($0.07/share) vs $0.67M loss in Q3 2024; G&A surged to $1.75M on listing costs.
- Cash and equivalents $3.11M at Sept 30, 2025, up from $0.87M at Dec 31, 2024.
- Closed global supply/development/license agreement with Medline for PermaFusion platform.
- Started trading on Nasdaq under TTRX on Oct 8, 2025; appointed two new board members.
- Commenced clinical trial of topical IL-36/IL-31 inhibitor for eczema.

## SEC filing metadata
- accession: 0001213900-25-109580
- form_type: 8-K
- ticker: TTRX
- cik: 0002023016
- company_name: Turn Therapeutics Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023016/000121390025109580/0001213900-25-109580-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023016/000121390025109580/ea0265413-8k_turn.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-109580
- JSON: https://secwatch.observer/filing/0001213900-25-109580.json
- Plain text: https://secwatch.observer/filing/0001213900-25-109580.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.